Safety and Efficacy of Intra‐Arterial Chemotherapy Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Head and Neck Squamous Cell Carcinoma

Documenti analoghi

• Risk Factors for Progressive Disease After Immune Checkpoint Inhibitor Therapy in Head and Neck Squamous Cell Carcinoma
  di: Seo Yoon Jang, et al.
  Pubblicazione: (2025)
• Response to Letter to the Editor: Fully COVID ‐19 Vaccinated Status Enhanced the Efficacy of Immune Checkpoint Inhibitors in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
  di: Chien‐Chung Wang, et al.
  Pubblicazione: (2026)
• Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review
  di: N. D. O'Donnell, et al.
  Pubblicazione: (2026)
• A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD ‐1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
  di: Mathias Fiedler, et al.
  Pubblicazione: (2026)
• Aberrant Splicing Burden Predicts Immune Infiltration and Prognosis in Head and Neck Squamous Cell Carcinomas
  di: Sandhya Kalavacherla, et al.
  Pubblicazione: (2025)